Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Apogee Therapeutics, Inc. Common Stock

Company price
None USD 0.00(0%)
Last update at 2026-11-16T10:21:03.945538Z
Market Cap
6782.42M

Momentum Score

…

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
34.34
Low
95.31
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Apogee Therapeutics, Inc. is a small publicly listed biopharmaceutical company; public disclosures are limited, but it appears focused on development of prescription therapeutics. Major long-term growth drivers may include clinical progress, regulatory approvals, strategic collaborations and eventual commercialization of approved products, which could support revenue and valuation expansion. Investors may find the company attractive for potential upside from successful development programs and niche market opportunities.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.01
ROE
-31.57%
Net Debt
-122.70M
ROCE
-31.41%
Diluted EPS TTM
-4.22

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Income before tax -255.56M -182.13M -83.98M -39.78M
Net income -255.84M -182.15M -83.98M -39.78M
Selling general administrative 70.88M 49.01M 24.58M 2.94M
Gross profit -1.42M -0.19M - -
Reconciled depreciation 1.42M 0.19M - -
Ebit -285.60M -216.87M -93.10M -30.76M
Ebitda -284.18M -216.68M -93.00M -30.73M
Depreciation and amortization 1.42M 0.19M 0.09M 0.03M
Operating income -285.60M -216.87M -93.00M -30.73M
Other operating expenses 285.60M 216.87M 93.00M 30.73M
Interest expense - - 0.00M 9.15M
Tax provision 0.28M 0.02M - -
Interest income 30.03M 34.74M 9.02M 0.09M
Net interest income 30.03M 34.74M 9.02M -9.06M
Income tax expense 0.28M 0.02M -0.09M -0.03M
Total revenue 0.00M 0.00M 0.00M 0.00M
Total operating expenses 284.18M 216.87M 93.00M 30.73M
Cost of revenue 1.42M 0.19M - -
Total other income expense net 30.03M 34.74M 9.02M -9.06M
Net income from continuing ops -255.84M -182.15M -83.98M -39.78M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total assets 937.13M 753.95M 401.40M 152.06M
Other current assets 11.17M 4.36M 2.95M 0.06M
Total liab 33.25M 37.16M 21.49M 9.98M
Total stockholder equity 903.88M 716.79M 379.91M -39.78M
Other current liab 23.18M 24.25M 17.31M 9.56M
Common stock 0.00M 0.00M - 4.39M
Capital stock 0.00M 0.00M 0.00M 0.00M
Retained earnings -561.76M -305.92M -123.77M -39.78M
Cash 131.55M 141.79M 118.32M 151.89M
Total current liabilities 27.91M 28.56M 20.56M 9.98M
Net debt -122.70M -129.96M -116.28M -151.89M
Short term debt 3.50M 3.23M 1.10M -
Short long term debt total 8.85M 11.83M 2.03M -
Other stockholder equity 1464.56M 1021.79M 503.35M 39.78M
Total current assets 741.36M 529.71M 398.41M 152.06M
Long term investments 172.73M 210.42M - -
Short term investments 598.64M 378.86M 277.14M 0.00M
Net receivables - 4.70M - -
Accounts payable 1.22M 1.07M 2.14M 0.42M
Accumulated other comprehensive income 1.08M 0.92M 0.33M -221.65M
Non currrent assets other 181.40M 0.50M 0.10M -
Non current assets total 195.78M 224.24M 3.00M 0.00M
Capital lease obligations 8.85M 11.83M 2.03M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Investments -174.43M -300.46M -273.91M 0.00M
Total cashflows from investing activities -179.57M -300.46M - -
Total cash from financing activities 396.49M 495.11M 315.39M 0.18M
Net income -255.84M -182.15M -83.98M -39.78M
Change in cash -10.53M 23.47M -33.57M -16.24M
Begin period cash flow 142.08M 118.61M 151.89M 168.13M
End period cash flow 131.55M 142.08M 118.32M 151.89M
Total cash from operating activities -227.45M -171.17M -74.76M -16.43M
Issuance of capital stock 389.63M 493.48M 315.39M 168.32M
Depreciation 1.42M 0.19M - -
Other cashflows from financing activities 396.49M 1.63M 0.32M 0.18M
Capital expenditures 5.15M 1.15M 0.17M 0.00M
Change in working capital -15.48M -2.00M 6.11M 9.81M
Stock based compensation 46.28M 23.33M 6.10M 2.14M
Other non cash items -3.82M -10.55M -2.98M 11.40M
Free cash flow -232.60M -172.33M -74.93M -16.43M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
NVO
Novo Nordisk A/S
0.98
2.41%
41.63 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc
-4.02
0.74%
538.60 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc
4.28
0.45%
955.47 29.07 20.12 7.57 3.82
ARGNF
argenx SE
64.70
7.19%
965.00 45.77 31.25 13.84 7.12

Profile*

Apogee Therapeutics, Inc. Common Stock

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Building 17, Waltham, MA, United States, 02453

650 394 5230

261

Name Title Year Born
Dr. Michael Thomas Henderson M.D. CEO & Director 1990
Ms. Jane Pritchett V. Henderson Chief Financial Officer 1966
Dr. Carl Linden Dambkowski M.D. Chief Medical Officer 1986
Dr. Rebecca Dabora Ph.D. Chief Technical Officer 1959
Ms. Noel Kurdi Vice President of Investor Relations NA
Mr. Matthew Batters J.D. General Counsel 1976
Ms. Emily Cox VP & Head of People NA
Ms. Wendy Aspden-Curran Senior Vice President of Clinical Operations NA
Dr. Drew Badger Ph.D. Senior VP and Head of Regulatory Affairs & Toxicology NA
Ms. Monica Forbes Senior Vice President of Finance 1976

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…